Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
Type:
Application
Filed:
October 26, 2018
Publication date:
December 24, 2020
Applicants:
Consejo Superior de Investigacions Cientificas (CSIS), Universidad Autonoma de Madrid, Centro de Investigacion Biomedica en Red de Enformedadas Neurodegerativas, Blumentech, S.L., Institute de Recerca de L'Hospital de la Santa Creu I Sant Pau
Inventors:
Ana Maria Perez Castillo, Jordi Riba Serra-No, Jose Angel Morales Garcia